Published in J Med Life on April 28, 2015
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun (2005) 4.06
Wound healing in glaucoma filtering surgery. Surv Ophthalmol (1988) 2.71
The National Survey of Trabeculectomy. II. Variations in operative technique and outcome. Eye (Lond) (2001) 2.63
Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma. J Ocul Pharmacol (1990) 2.20
Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol (2003) 2.02
Morphologic classification of filtering blebs after glaucoma filtration surgery: the Indiana Bleb Appearance Grading Scale. J Glaucoma (2003) 1.64
Regulation of scar formation by vascular endothelial growth factor. Lab Invest (2008) 1.51
Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology (2008) 1.39
Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol (2007) 1.35
Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci (2009) 1.23
Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. Ophthalmology (2000) 1.22
The role of the immune system in conjunctival wound healing after glaucoma surgery. Surv Ophthalmol (2000) 1.06
Wound healing in an animal model of glaucoma fistulizing surgery in the rabbit. Ophthalmic Surg (1989) 1.03
Vascular changes after intra-bleb injection of bevacizumab. J Glaucoma (2008) 1.00
Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: a case series. Korean J Ophthalmol (2010) 0.91
Clinical use of Bevacizumab in treating refractory glaucoma. J Med Life (2015) 0.76
The role of Spectral Domain Optical Coherence Tomography in monitoring uncontrolled hypertensive type 2 diabetic patients. J Med Life (2014) 0.75
Hydroxyapatite ocular implant and non-integrated implants in eviscerated patients. J Med Life (2015) 0.75